Renal Carcinoma Clinical Trial
Official title:
Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)
Microphthalmia transcription factor (MiT) family translocation renal cell carcinomas (TRCC) are rare subtypes of kidney cancers, which often arise in children and young adults. TRCC are characterized by translocations affecting transcription factors: Transcription Factor Binding To Immunoglobulin Heavy Constant Mu Enhancer 3 (TFE3) and Transcription Factor EB (TFEB). Little is known about TRCC molecular heterogeneity, in particular their transcriptomic and epigenetic subtype classification. Clinical behavior of TRCC is varying with age and Tumor, Node, Metastasis (TNM) stage. However, the biological basis of this aggressiveness is poorly understood. PURPOSE: The primary goal of this study is to decipher specific alterations in aggressive TRCC, defined as cases with metastatic dissemination at diagnosis. To tackle this problem, a retrospective cohort of TRCC cases in children and young adults will be created. We will then perform integrative comprehensive multi-omics analysis of these tumors to identify genetic, epigenetic and immune biomarkers associated with metastatic behavior in a training and validation datasets. Comparison of the multi-omics data will be compared to other type of rare Kidney tumors as well as clear-cell renal cell carcinomas
This retrospective cohort study aims to allow tumor collection of TRCC from three different networks: the French research network in renal cancer (UroCCR), the International Society of Paediatric Oncology (SIOP) database and the network for rare renal carcinomas (CARARE). Those samples will be divided in training and validation datasets. We will also collect samples from patients with other rare kidney cancers and clear-cell renal cell carcinomas allowing comparisons of similarity and differences between these tumors. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04718584 -
the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
|
Phase 2 | |
| Recruiting |
NCT03114826 -
Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients
|
N/A | |
| Recruiting |
NCT02928692 -
Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium
|
Phase 3 | |
| Recruiting |
NCT03475953 -
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03638206 -
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03786796 -
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
|
Phase 2 | |
| Completed |
NCT03064308 -
The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery
|
N/A | |
| Recruiting |
NCT06290427 -
Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K)
|
N/A | |
| Withdrawn |
NCT02370342 -
Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery
|
N/A | |
| Not yet recruiting |
NCT06318871 -
A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Combination With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
|
Early Phase 1 | |
| Recruiting |
NCT04773951 -
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
|
Phase 1 |